Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
NEW ORLEANS, April 23, 2018 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 19, 2018 to file lead plaintiff applications in a securities class action lawsuit against Myriad Genetics, Inc. (Nasdaq:MYGN), if they purchased the Company’s securities between August 13, 2014 through March 12, 2018, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Utah.
What You May Do
If you purchased securities of Myriad and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-mygn/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by June 19, 2018.
About the Lawsuit
Myriad Genetics and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On March 12, 2018, the Company revealed that it received a subpoena from the Department of Health and Human Services, regarding “an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid,” specifically relating to the Company’s hereditary cancer testing dating back to January 1, 2014 (less than four months after the Company launched its myRisk test in September 2013) to the date of the subpoena’s issuance.
On this news, the price of Myriad’s shares plummeted over 12.14%.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
206 Covington St.
Madisonville, LA 70447
